人工胸腺オルガノイドによるヒトiPS細胞由来CD4⁺T細胞療法の開発と評価

ad

2026-04-23 京都大学iPS細胞研究所

京都大学iPS細胞研究所(CiRA)の研究グループは、人工胸腺オルガノイドを用いてヒトiPS細胞からCAR導入CD4⁺T細胞(CAR-iCD4⁺T細胞)を作製し、その高い抗腫瘍効果を実証した。作製細胞はヘルパー機能と細胞傷害機能の両方を備え、CD8⁺T細胞と比べて高い増殖能とメモリー様特性を示し、疲弊しにくいことが確認された。血液がんモデルでは、CAR-iCD4⁺T細胞単独でCD8⁺T細胞や併用療法を上回る持続的な治療効果を発揮した。さらにサイトカイン産生や免疫細胞活性化能にも優れ、長期的な免疫応答を維持できる可能性が示された。本成果は、iPS細胞由来の「既製品型」CAR-T療法の実現と、より持続的かつ高効率ながん免疫療法の開発に貢献すると期待される。

人工胸腺オルガノイドによるヒトiPS細胞由来CD4⁺T細胞療法の開発と評価
図1. iCD4+T細胞のヘルパー表現型および機能

<関連情報>

適応型CAR-iPSC-CD4⁺ T細胞は、持続的なALL制御においてCD8⁺ T細胞よりも優れた性能を示す Adaptive-like CAR-iPSC-CD4⁺ T cells outperform CD8⁺ counterparts in sustained ALL control

Qingyi Guo,Chaoqi Zhang,Bo Wang,Shoichi Iriguchi,Akihiro Ishikawa,Atsutaka Minagawa,Tomoko Ishii,Yohei Kawai & Shin Kaneko
Inflammation and Regeneration  Published:03 January 2026
DOI:https://doi.org/10.1186/s41232-025-00402-4

Abstract

Background

Induced pluripotent stem cell (iPSC)–derived T cells offer a renewable source for off-the-shelf immunotherapy. With the advent of the artificial thymic organoid (ATO) method, the in vitro differentiation of CD4+ T cells from iPSCs has also become feasible. CD4⁺ T cells have shown superior longevity, resistance to exhaustion, and helper functions in primary settings, but whether iPSC-derived CD4⁺ T cells retain these features remains unclear.

Methods

In this study, CD4⁺ T cells were differentiated from human iPSCs using the ATO system. Primary T cells served as controls to evaluate the phenotypic and activation features of iPSC-derived CD4⁺ and CD8⁺ T cells. To assess antitumor function, we generated CD19-BBζ CAR-iPSC-T cells and employed a hematologic malignancy model using NALM6 acute lymphoblastic leukemia (ALL) cells. Both short-term and long-term cytotoxicity assays were conducted to compare iPSC-derived CD4⁺ and CD8⁺ T cells in terms of killing efficiency, cytokine secretion, persistence, exhaustion phenotype, and proliferative capacity. The helper function of iPSC-derived CD4⁺ T cells toward CD8⁺ T cells was further evaluated by Ki-67 staining and proliferation assays. Statistical analyses were performed using GraphPad Prism.

Results

Our study demonstrated that iPSC-derived CD4⁺ T cells exhibited both helper- and cytotoxic-like features. Compared with iPSC-derived CD8⁺ T cells or CD4⁺/CD8⁺ mixtures, iPSC-derived CD4⁺ T cells showed superior proliferation, cytokine secretion, and sustained cytotoxicity following CAR transduction. They also promoted the expansion of iPSC-derived CD8⁺ T cells and displayed helper-like functions with increased resistance to exhaustion.

Conclusions

Although not identical to primary CD4⁺ T cells, iPSC-derived CD4⁺ T cells recapitulated key functional advantages, especially sustained antitumor activity, supporting their value as a renewable, off-the-shelf source for next-generation CAR-T therapies.

細胞遺伝子工学
ad
ad
Follow
ad
タイトルとURLをコピーしました